Investor Update

Basel, 26 February 2014

Reminder: Upcoming changes to the Roche ADR (RHHBY)

Roche (SIX: RO, ROG; OTCQX: RHHBY), as previously announced on 10 February 2014, plans to implement a change to its US ADR programme (RHHBY, CUSIP 771195104) in the near future. The planned change comprises a change in the ADR ratio from now 4 (four) ADRs (RHHBY) per 1 (one) underlying non-voting equity security (ROG) to future 8 (eight) RHHBYs per 1 (one) ROG.

ADR holders are kindly reminded that the estimated first day of trading with the new ADR ratio will be Thursday 27 February 2014.

For more details we politely refer to our Investor Update from 10 February 2014:

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.